BOULDER, CO, October 4th, 2022 – AmideBio, LLC, a privately held biopharmaceutical company, announced today that it has received $2.69M in funding through a Phase IIB Small Business Innovation Research …
Dr. Mikhail (Misha) Plam, AmideBio Co-founder, Obituary (December 1, 1936-February 21, 2022)
https://www.legacy.com/us/obituaries/dailycamera/name/mikhail-plam-obituary?id=33261146
AMIDEBIO Awarded SBIR Phase I Grant to Develop Novel Glucose Responsive Insulin Therapeutics
BOULDER, CO, March 8, 2021 – AmideBio, LLC, a privately-held biopharmaceutical company, announced today that it has received $300,000 in funding through a Phase I Small Business Innovation Research (SBIR) …
AMIDEBIO Granted Rare Pediatric Disease Designation by FDA for Novel Solution Stable Glucagon
AmideBio, LLC, a privately held biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) Offices of Pediatric Therapeutics and Orphan Products Development granted a rare pediatric disease …
AMIDEBIO Granted Orphan Drug Designation by FDA for Novel Solution Stable Glucagon
AmideBio, LLC, a privately held biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) Office of Orphan Products Development granted an orphan drug designation to AmideBio’s glucagon …
AMIDEBIO Awarded $1.56M SBIR Phase II Grant to Further Development of its Novel Glucagons for the Treatment of Hyperinsulinism
AmideBio, LLC, a privately held biopharmaceutical company, announced today that it has received $1.56M in funding through a Phase II Small Business Innovation Research (SBIR) grant from the National Institute …
David Brunel Takes Over Chairmanship at AmideBio
BOULDER, CO, November 16, 2018 – AmideBio LLC, a privately held biopharmaceutical company, announced today that David Brunel, a board member of AmideBio, has assumed the role of Chairman of …
Diabetes Industry Veteran Pawel Fludzinski, Ph.D. assumed role of Company President of AmideBio
BOULDER, CO, September 4, 2018 – AmideBio LLC, a privately held biopharmaceutical company, announced today that Pawel Fludzinski, Ph.D. has assumed the role of Company President in addition to Chief …
Diabetes Industry Veteran Pawel Fludzinski, Ph.D. Named CEO of AmideBio
AmideBio LLC, a privately held biopharmaceutical company, announced today that Dr. Pawel Fludzinski has joined the Company as its new Chief Executive Officer. With his extensive background developing drugs targeting diabetes at …
Charles A. Stanley MD, joins AmideBio’s Scientific Advisory Board
BOULDER, CO, November 14, 2017 – AmideBio LLC, a privately held biopharmaceutical company, announced today that Charles A. Stanley MD will join its scientific advisory board. Dr. Stanley is a …
- Page 1 of 2
- 1
- 2